Drug Profile
Research programme: chimeric antigen receptor T cell therapeutics - Noile-Immune Biotech/Takeda
Alternative Names: Autologous prime CAR-T - Noile-Immune Biotech; NIB-101; NIB-104; NIB-105Latest Information Update: 02 Aug 2022
Price :
$50
*
At a glance
- Originator Yamaguchi University
- Developer Noile-Immune Biotech; Takeda
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours